Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Measure From RADIANCE Data Suggests Ozanimod More Effective in Slowing MS Disease Activity
September 11th 2019A poster featuring a post-hoc exploratory analysis of measures of thalamic volume from RADIANCE was presented September 11, 2019, at ECTRIMS 2019, the 35th Annual Congress of the European Committee for Treatment and Research in Multiple Sclerosis, taking place in Stockholm, Sweden.
Dapagliflozin Cuts Risk of CV Death, Worsening of Heart Failure 26%, Whether Diabetes Present or Not
September 1st 2019Dapagliflozin, sold by AstraZeneca as Farxiga, cut the risk of cardiovascular (CV) death and worsening of heart failure (HF) by 26% among patients with reduced ejection fraction alongside standard of care, according to results of a landmark phase 3 study presented Sunday at the European Society of Cardiology 2019 Congress. Results confirmed that the sodium glucose co-transporter 2 (SGLT2) inhibitor, already approved to treat type 2 diabetes (T2D), is just as effective in preventing CV death and HF events in patients who do not have T2D.
Study Finds Imaging Technique Could Replace Riskier Diagnostic Method for Diabetic Retinopathy
August 30th 2019Diabetic retinopathy costs the United States $6.2 billion a year. Better screening techniques that can catch neurodegeneration at earlier stages have the potential to cut costs and improve quality of life for patients.
AstraZeneca's Dapagliflozin Meets Primary End Point in Heart Failure Trial
August 20th 2019Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure includes patients with and without type 2 diabetes, although the topline results did not specify if results were similar in these 2 populations.
Eating Behaviors May Help Physicians Diagnose Autism, Penn State Study Finds
July 22nd 2019Unusual eating behavior can be seen in 70% of children who have autism, and it is so characteristic of this group that hypersensitivity to food textures or temperatures can be a reason for parents to look into an autism diagnosis, according to new research from Penn State College of Medicine.